Ignite Creation Date:
2025-12-25 @ 1:06 AM
Ignite Modification Date:
2026-01-01 @ 10:32 PM
Study NCT ID:
NCT05243693
Status:
RECRUITING
Last Update Posted:
2022-02-17
First Post:
2022-01-02
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Brentuximab Vedotin Plus DHAP in Relapsed or Refractory Hodgkin's Lymphoma
Sponsor:
National Cancer Center, Korea
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03
Start Date Type:
ESTIMATED
Primary Completion Date:
2024-02-28
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-03-31
Completion Date Type:
ESTIMATED
First Submit Date:
2022-01-02
First Submit QC Date:
None
Study First Post Date:
2022-02-17
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2022-02-12
Last Update Post Date:
2022-02-17
Last Update Post Date Type:
ACTUAL